What is claimed is:

Claim 1. Use of 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof in the manufacture of a medicament for preventing, reducing, or delaying the reoccurrence of breast cancer in a subject following local treatment and neoadjuvant or adjuvant chemo therapy, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

Claim 2. Use of 4-[(3-{[4-(cyclopropane-carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof in the manufacture of a medicament for treating a subject with breast cancer following local treatment and neoadjuvant or adjuvant chemo therapy, wherein a therapeutically effective amount of the medicament is to be used for the adjuvant treatment of the subject.

Claim 3. 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use in (or for use in the manufacture of a medicament for) the adjuvant treatment, after local treatment and neo adjuvant or adjuvant chemotherapy, of a subject having breast cancer.

Claim 4. The use of claim 1 or 2 or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of claim 3, wherein the subject has one or more germline BRCA1 and/or BRCA2 gene mutations.

Claim 5. The use or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of claim 4 wherein the germline BRCA1 and/or BRCA2 gene mutations are pathogenic or likely pathogenic (gBRCA-P/LP-variant).

Claim 6. Use of 4-[(3-{[4-(cyclopropane-carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof in the manufacture of a medicament for improving invasive disease survival (or overall survival or distant-disease-free survival) by providing adjuvant treatment to a subject with a prior diagnosis of germline mutated BRCA1 and/or BRCA2 breast cancer, said subject having previously had

local treatment and neoadjuvant or adjuvant chemotherapy, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

Claim 7. The use of any one of claims 1, 2, or 4 to 6, or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of any one of claims 3 to 5, wherein the breast cancer is HER2-negative breast cancer.

Claim 8. The use or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of claim 7 wherein the breast cancer is HER2-negative early stage (Stage II-III) breast cancer.

Claim 9. The use of any one of claims 1, 2, or 4 to 8, or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of any one of claims 3 to 5, 7 or 8, wherein the local treatment comprises surgery so as to remove breast cancer tissue, and optionally includes radiotherapy

Claim 10. The use of any one of claims 1, 2, or 4 to 9, or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of any one of claims 3 to 5, or 7 to 9, wherein the subject has completed at least 6 cycles of neoadjuvant or adjuvant chemotherapy.

Claim 11. The use or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of claim 10, wherein the neoadjuvant or adjuvant chemotherapy contains anthracyclines, taxanes or a combination of both.

Claim 12. The use of any one of claims 1, 2, or 4 to 11, or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of any one of claims 3 to 5, or 7 to 11, wherein the therapeutically effective amount of olaparib is 300mg administered twice daily.

Claim 13. The use or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for

use of claim 12 wherein the therapeutically effective amount of olaparib is 300mg administered twice daily for a period of 1 year.

Claim 14. The use of any one of claims 1, 2, or 4 to 13, or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of any one of claims 3 to 5, or 7 to 13, wherein invasive disease-free survival is improved relative to subjects treated with placebo.

Claim 15. The use or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of claim 14 wherein the probability of invasive disease free survival is about 86% at about 3 years following initiation of olaparib treatment.

Claim 16. The use or the 4-[(3-{[4-(cyclopropane carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof for use of claim 14 wherein the probability of invasive disease free survival is improved by from about 1 to about 10% at about 3 years following initiation of olaparib treatment, such as from about 1 to about 9% at about 3 years, such as from about 5 to about 9% at about 3 years.

Claim 17. The use of claim 6 wherein, wherein distant disease-free survival is improved relative to subjects treated with placebo.

Claim 18. The use of claim 17, wherein the improvement in distant disease free survival at about 3 years is up to about 8%, such as up to about 7%, such as from about 1 to about 8%, such as from about 1 to about 7%, such as from about 3% to about 8%, such as from about 3% to about 7%.